Legal Representation
Attorney
Diane B Melnick
USPTO Deadlines
Next Deadline
1253 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20230606)
Due Date
June 06, 2029
Grace Period Ends
December 06, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 4, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Sep 6, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Oct 3, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Sep 7, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Sep 7, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Sep 6, 2023 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jun 6, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jun 6, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 5, 2023 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| May 17, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| May 17, 2023 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Mar 21, 2023 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Mar 21, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 21, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 1, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 1, 2023 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Mar 1, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 14, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 6, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 5, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 5, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 29, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 11, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 11, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 21, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jul 20, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 19, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 21, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Dec 17, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 16, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations, namely a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; medicinal preparations for the treatment of infectious diseases and for use in oncology; therapeutic preparations for treating cardiovascular diseases; pharmaceutical and medicinal preparations and substances for the treatment of diabetes; pharmaceutical and medicinal preparations and substances for use in oncology; pharmaceutical and medicinal preparations, substances and compositions for the treatment and/or prevention of cancer; pharmaceutical and medicinal preparations and substances for the treatment of neurodegenerative disorders; pharmaceutical and medicinal preparations and substances for the treatment of metabolic disorders; pharmaceutical and medicinal preparations and substances for the treatment of musculoskeletal disorders; pharmaceutical and medicinal preparations and substances for the treatment of osteoarthritis; pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders and rare diseases
Class 042
Scientific research; pharmaceutical research; medical research services in the field of medicines; technical advice for third parties in the field of development of pharmaceutical products; product development for third parties in the field of pharmaceutical products; research and development of pharmaceuticals and medicinal preparations and substances for third parties; research and development of pharmaceuticals and medicinal preparations and substances for the treatment of cancer; research and development of pharmaceuticals and medicinal preparations and substances for treating inflammation; research and development of pharmaceuticals and medicinal preparations and substances for the treatment of neurodegenerative disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of metabolic disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of musculoskeletal disorders; research and development of pharmaceutical and medicinal preparations and substances for the treatment of osteoarthritis; research and development of pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders and rare diseases
Additional Information
Design Mark
The mark consists of a stylized design of a tree surrounded by shaded leaves, to the right of which is the stylized wording "FLORATEK PHARMA".
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"